Risk factors for adverse drug events: A 10-year analysis

被引:99
|
作者
Evans, RS
Lloyd, JF
Stoddard, GJ
Nebeker, JR
Samore, MH
机构
[1] LDS Hosp, Dept Med Informat, Salt Lake City, UT 84143 USA
[2] Univ Utah, Sch Med, LDS Hosp & Intermt Hlth Care, Salt Lake City, UT USA
[3] Univ Utah, Sch Med, Div Clin Epidemiol, Biostat Sect, Salt Lake City, UT 84112 USA
[4] Univ Utah, Sch Med, Div Clin Epidemiol, Salt Lake City, UT 84112 USA
[5] Univ Utah, Sch Med, Dept Med Informat, Salt Lake City, UT USA
关键词
adverse drug events; quality improvement; risk factors;
D O I
10.1345/aph.1E642
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Many adverse drug events (ADEs) are the result of known pharmacologic properties, and some result from medication errors. However, some are the result of patient-specific risk factors. OBJECTIVE: To identify inpatient risk factors for ADEs. METHODS: Conditional logistic regression was used to analyze all pharmacist-verified ADEs by therapeutic class of drugs and severity during a 10-year study period. All inpatients >= 18 years of age from a 520-bed tertiary teaching hospital were included. Each case patient was matched with up to 16 control patients. Odds ratios for patient factors associated with ADEs were calculated from different therapeutic classes of drugs. RESULTS: Odds ratios for numerous risk factors were identified for 4376 ADEs and were found to vary depending on therapeutic classification. The risk factors for the different classifications were grouped by (1) patient characteristics-female (OR 1.5-1.7), age (0.7-0.9), weight (1.2-1.4), creatinine clearance (0.8-4.7), and number of comorbidities (1.1-12.6); (2) drug administration-dosage (1.2-3.7), administration route (1.4-149.9), and number of concomitant drugs (1.2-2.4); and (3) patient type-service (1.2-4.9), nursing division (1.5-3.8), and diagnosis-related group (1.5-5.7). CONCLUSIONS: Some risk factors are consistent for all ADEs and across multiple therapeutic classes of drugs, while others are class specific. High-risk agents should be closely monitored based on patient characteristics (gender, age, weight, creatinine clearance, number of comorbidities) and drug administration (dosage, administration route, number of concomitant drugs).
引用
收藏
页码:1161 / 1168
页数:8
相关论文
共 50 条
  • [31] Adverse events during apheresis: A 10-year experience at a tertiary academic medical center
    Kundrapu, Sirisha
    Datla, Sireesha
    Griffin, Vanessa
    Maitta, Robert W.
    JOURNAL OF CLINICAL APHERESIS, 2019, 34 (05) : 528 - 536
  • [32] Sirtfood intake in relation to the 10-year risk of major adverse cardiovascular events: a population-based cohort study
    Golzarand, Mahdieh
    Estaki, Saghar
    Mirmiran, Parvin
    Azizi, Fereidoun
    NUTRITION & METABOLISM, 2024, 21 (01)
  • [33] Evaluation of ischemic cardiovascular and cerebrovascular adverse events by 10-year cardiovascular risk score in patients with migraine treated with erenumab
    Kudrow, D.
    Starling, A. J.
    Ailani, J.
    Dafer, R. M.
    Zhang, F.
    Xue, F.
    Patel, N.
    Nelson, R.
    HEADACHE, 2021, 61 : 127 - 127
  • [34] Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry
    Doolan, Brent J.
    Koye, Digsu
    Ling, Joanna
    Cains, Geoffrey D.
    Baker, Christopher
    Foley, Peter
    Dolianitis, Con
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 (01) : E47 - E54
  • [35] Adverse Events with Fatal Outcome, a 10-Year Survey of Iranian Spontaneous Reports Database
    Yousefian, Shadi
    Shalviri, Gloria
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S96 - S96
  • [36] Cardiovascular risk factors in the elderly: a 10-year follow-up survival analysis
    de Sousa, Thais Vilela
    Ruiz Zimmer Cavalcante, Agueda Maria
    Lima, Nathalia Xavier
    Souza, Jennifer Siqueira
    Lima Sousa, Ana Luiza
    Brasil, Virginia Visconde
    Mendonca Vieira, Flaviana Vely
    Guimaraes, Janaina Valadares
    de Matos, Marcos Andre
    Silveira, Erika Aparecida
    Pagotto, Valeria
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2023, 22 (01) : 43 - 52
  • [37] RISK FACTORS FOR DEVELOPMENTAL DYSPLASIA OF THE HIP: 10-YEAR EXPERIENCE
    Kural, Bahar
    Devecioglu, Esra
    Gokcay, Gulbin
    Eren, Tijen
    Yilmazbas, Pinar
    Gokcay, Irfan
    ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A207 - A208
  • [38] Sex differences in risk factors for HIV seroconversion among injection drug users -: A 10-year perspective
    Strathdee, SA
    Galai, N
    Safaiean, M
    Celentano, DD
    Vlahov, D
    Johnson, L
    Nelson, KE
    ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (10) : 1281 - 1288
  • [39] Clinical risk factors and blood protein biomarkers of 10-year pneumonia risk
    Lee, Ming-Ming
    Zuo, Yi
    Steiling, Katrina
    Mizgerd, Joseph P.
    Kalesan, Bindu
    Walkey, Allan J.
    PLOS ONE, 2024, 19 (07):
  • [40] 10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 Inhibitors
    Lowe, Gregory
    Costabile, Raymond A.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (01): : 265 - 270